MarketPeel
Insider Trading Intelligence
CG

Christopher Thomas Giordano

TENX
CEO · TENAX THERAPEUTICS, INC. · CIK 0001871714
FILING MIX · LIFETIME100%/0%
BUYS
8
SELLS
0
TOTAL VALUE
$20.0K
COMPANIES
1
ACTIVE SINCE
Jun 2022
HOLDINGS NOW
450,000
AVG SELL PX
TRADE KIND
SHOWING 8 / 8
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 6 pending
Forward-return performance of every backtestable P/S trade by Christopher Thomas Giordano, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+100.00%+24.86%+3.00%+21.87%+20.05%
14d3+100.00%+21.38%+3.78%+17.60%+16.47%
30d3+100.00%+71.93%+3.17%+68.77%+65.72%
60d3+100.00%+113.74%+4.33%+109.41%+109.27%
90d3+100.00%+65.04%+3.89%+61.15%+58.95%
180d3+100.00%+58.91%+12.75%+46.16%+45.12%
1y3(3 pending)
2y3(3 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TENX · 450,000 shares · as of Jan 9, 2026
0350,000700,0001,050,0001,400,0002023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 8 buys / 0 sellsCOVERAGE · 16 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
TENX
TENAX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
450,000450,000Jan 9, 2026Jan 13, 2026View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASE
CEO
538$7.59$4.1K2,605Nov 20, 2025Nov 20, 2025View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASE
CEO
455$7.51$3.4K2,067Nov 19, 2025Nov 20, 2025View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASE
CEO
1,612$7.75$12.5K1,612Nov 18, 2025Nov 20, 2025View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,400,0001,400,000May 16, 2025May 20, 2025View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,250,0001,250,000Dec 10, 2024Dec 12, 2024View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
437437May 17, 2024May 21, 2024View →
TENX
TENAX THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
200,000200,000Jun 9, 2022Jun 10, 2022View →
Other insiders · TENX
Loading peer insiders…
About this filer
CIK 0001871714
ROLE
CEO
PRIMARY
TENX
COMPANIES
1
ACTIVE SINCE
Jun 2022
MARKETPEEL · /INSIDER/0001871714DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback